Equity research analysts at Berenberg have GBX 220.00 target price per share on XLMedia Plc (LON:XLM). Berenberg’s target price per share suggests a potential upside of 8.11% from the company’s last stock close. The rating was revealed in a note on Thursday morning.
Among 8 analysts covering Affimed Therapeutics (NASDAQ:AFMD), 5 have Buy rating, 0 Sell and 3 Hold. Therefore 63% are positive. Affimed Therapeutics had 17 analyst reports since August 6, 2015 according to SRatingsIntel. The rating was maintained by Oppenheimer with “Buy” on Tuesday, August 1. The firm earned “Hold” rating on Thursday, May 19 by Jefferies. The company was initiated on Thursday, December 10 by Laidlaw. The rating was initiated by Jefferies with “Hold” on Wednesday, September 9. The rating was maintained by Jefferies on Thursday, August 31 with “Hold”. The firm earned “Market Perform” rating on Thursday, May 19 by Leerink Swann. The rating was upgraded by Zacks on Monday, August 10 to “Sell”. The stock of Affimed N.V. (NASDAQ:AFMD) earned “Outperform” rating by Oppenheimer on Thursday, August 6. The stock of Affimed N.V. (NASDAQ:AFMD) has “Market Perform” rating given on Friday, August 12 by Leerink Swann. The firm has “Outperform” rating given on Friday, December 4 by Wells Fargo. See Affimed N.V. (NASDAQ:AFMD) latest ratings:
31/08/2017 Broker: Jefferies Rating: Hold New Target: $2.5 Maintain
01/08/2017 Broker: Oppenheimer Rating: Buy New Target: $7.0000 Maintain
14/07/2017 Broker: SunTrust Rating: Buy New Target: $7 Initiates Coverage On
12/06/2017 Broker: Jefferies Rating: Hold New Target: $2.5000 Maintain
XLMedia PLC, an online performance marketing company, attracts paying users from various online and mobile channels, and directs them to online businesses. The company has market cap of 415.04 million GBP. It operates through Publishing, Media, and Partners Network divisions. It has a 15.62 P/E ratio. The firm owns approximately 2,000 informational Websites in 17 languages for gambling operators to attract online gaming players; creates and deploys online media campaigns across various languages and platforms; and manages a pool of affiliates through its proprietary systems, providing them with ongoing support and access to multiple operators.
Among 2 analysts covering XLMedia Plc (LON:XLM), 2 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. XLMedia Plc has GBX 220 highest and GBX 103 lowest target. GBX 165.50’s average target is -18.51% below currents GBX 203.1 stock price. XLMedia Plc had 18 analyst reports since August 5, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Monday, September 11 by Berenberg. The stock of XLMedia PLC (LON:XLM) earned “Buy” rating by Berenberg on Thursday, May 18. Liberum Capital maintained it with “Buy” rating and GBX 111 target in Tuesday, January 19 report. The firm earned “Buy” rating on Tuesday, April 25 by Berenberg. The firm earned “Buy” rating on Monday, September 7 by Liberum Capital. Liberum Capital maintained the stock with “Buy” rating in Thursday, January 21 report. The rating was maintained by Liberum Capital with “Buy” on Thursday, November 12. On Wednesday, September 2 the stock rating was maintained by Liberum Capital with “Buy”. The stock has “Buy” rating by Berenberg on Thursday, February 9. The stock of XLMedia PLC (LON:XLM) has “Buy” rating given on Monday, August 14 by Berenberg.
The stock increased 0.54% or GBX 1.1 during the last trading session, reaching GBX 203.1. About 76,142 shares traded. XLMedia PLC (LON:XLM) has 0.00% since December 7, 2016 and is . It has underperformed by 16.70% the S&P500.
The stock decreased 5.26% or $0.1 during the last trading session, reaching $1.8. About 431,907 shares traded or 45.74% up from the average. Affimed N.V. (NASDAQ:AFMD) has declined 19.09% since December 7, 2016 and is downtrending. It has underperformed by 35.79% the S&P500.
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in Germany and internationally. The company has market cap of $80.41 million. The Company’s lead candidate is AFM13, a natural killer cell TandAb designed for the treatment of CD30-positive (CD30+) B- and T-cell malignancies, including Hodgkin lymphoma. It currently has negative earnings. The companyÂ’s product candidates include AFM24, a NK-cell that treats epidermal growth factor receptor expressing solid tumors, such as lung, head, neck, and colon cancers; AFM26, which binds to B-cell maturation antigen (BCMA) for the treatment of multiple myeloma; and Trispecific Abs for the treatment of multiple myeloma.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.